.jpg)
In a report released today, Jason Kolbert from H.C. Wainwright initiated coverage with a Buy rating on Cytori Therap (NASDAQ: CYTX) and a price target of $4. The company’s shares closed on Friday at $0.24, close to its 52-week low of $0.22.
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -6.1% and a 35.6% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Cytori Therap is Strong Buy and the average price target is $2.23, representing an 831.5% upside.
In a report issued on April 30, Maxim Group also maintained a Buy rating on the stock with a $2 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.21 and a one-year low of $0.22. Currently, Cytori Therap has an average volume of 622.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytori Therapeutics, Inc. is a late stage cell therapy company which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E.
